Keywords
Quality of life
Patient-reported outcome measures
Psychosocial impact
Therapeutics
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze and synthesize the clinical, therapeutic, and psychosocial factors that influence the quality of life in individuals with chronic inducible urticaria. Methods: This is an integrative literature review, conducted in the PubMed, Scopus, SciELO, and Web of Science databases. Twenty-Four articles published since 2017 were included, strictly selected according to the PRISMA flowchart guidelines. Results: The disease imposes a multidimensional burden, with baseline scores indicating severe impact on quality of life and high therapeutic refractoriness. The impairment includes reduced productivity and severe psychosocial repercussions, such as sexual dysfunction and spiritual impairment. Traditional assessment instruments tend to underestimate the true impact of the disease by failing to capture the behavioral burden generated by hypervigilance and trigger avoidance. Final considerations: It can be considered that the impact of the condition is profound and multifaceted, being determined by clinical control. The study highlights the need to adopt specific patient-reported outcome measures for a reliable assessment and personalized management.
References
BAUDY V, et al. Impact of Chronic Spontaneous or Inducible Urticaria on Occupational Activity. Acta Dermato-Venereologica, 2024; 104: e36122.
BUMBĂCEA RS, et al. Management problems in severe chronic inducible urticaria: Two case reports. Experimental and Therapeutic Medicine, 2019; 18(2): 960-963.
CAN PK, KOCATÜRK E. Avaliação das respostas ao tratamento com as ferramentas recomendadas em pacientes com dermografismo sintomático. Turkderm-Turk Arch Dermatol Venereology, 2019; 53(4): 139-143.
CHEN Y, et al. Analysis of the Efficacy and Recurrence of Omalizumab Use in the Treatment of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria. International Archives of Allergy and Immunology, 2023; 184(8): 768-777.
DIAS DE CASTRO E, et al. Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal. European Annals of Allergy and Clinical Immunology, 2018; 50(6): 263-268.
DIAS G, et al. Clinical experience of a chronic urticaria referral university center. European Annals of Allergy and Clinical Immunology, 2020; 52(2): 78-84.
DORTAS JUNIOR SD, et al. Spiritual well-being and quality of life are impaired in chronic urticaria. European Annals of Allergy and Clinical Immunology, 2021; 53(5): 221-227.
HAWRO T, et al. The Urticaria Activity Score-Validity, Reliability, and Responsiveness. The Journal of Allergy and Clinical Immunology: In Practice, 2018; 6(4): 1185-1190.
KILIC A, et al. Sexual Functions are Impaired in Males and Females with Chronic Spontaneous and Inducible Urticaria; A Controlled Study. Dermatology Practical & Conceptual, 2025; 15(1): e2025001.
KOCATÜRK E, et al. Validation of the Turkish version of the Urticaria Control Test: Correlation with other tools and comparison between spontaneous and inducible chronic urticaria. World Allergy Organization Journal, 2019; 12(1): 100008.
KULTHANAN K, et al. Checklist for a complete chronic urticaria medical history: an easy tool. World Allergy Organization Journal, 2017; 10(1): 1-5.
KUMARAN MS, et al. Decoding the variability in clinical and laboratory profiles of Chronic Inducible Urticaria vs. Chronic Spontaneous Urticaria - a retrospective study from a tertiary care center. Archives of Dermatological Research, 2024; 316(10): 703.
LEE SJ, et al. Natural course and prognostic factors of chronic urticaria in Korean children: A single center experience. Asian Pacific Journal of Allergy and Immunology, 2019; 37(1): 25-30.
MAO Y, et al. Clinical difference between single subtype and mixed subtype chronic urticaria: A retrospective study. Indian Journal of Dermatology, Venereology and Leprology, 2022; 88: 167-173.
MASTROLONARDO M, et al. Long term treatment with omalizumab in adolescent with refractory solar urticaria. Italian Journal of Pediatrics, 2021; 47(1): 195.
MAURER M, et al. Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study. World Allergy Organization Journal, 2018; 11(1): 31.
METZ M, et al. A randomized, double-blind, placebo-controlled, crossover study to evaluate the efficacy of hydroxyzine... for treating chronic cold urticaria. Clinical and Experimental Dermatology, 2018; 43(8): 871-876.
OTT, H. Chronische Urtikaria im Kindesalter: Rationale Diagnostik und Therapie. Der Hautarzt, v. 68, n. 7, p. 571-582, jul. 2017. DOI: 10.1007/s00105-017-3985-5.
RUJITHARANAWONG C, et al. Natural history and clinical course of patients with dermographism in a tropical country: a questionnaire-based survey. Asia Pacific Allergy, 2022; 12(4): e39.
SÁNCHEZ-BORGES M, et al. The challenges of chronic urticaria part 2: Pharmacological treatment, chronic inducible urticaria, urticaria in special situations. World Allergy Organization Journal, 2021; 14(6): 100546.
TERHORST-MOLAWI D, et al. Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria. Allergy, 2022; 78(5): 1364-1367.
WELLER K, et al. Dermographism control test: Development and validation... Journal of the European Academy of Dermatology and Venereology, 2018; 32(8): 1335-1342.
WELLER K, et al. Development of the symptomatic dermographism quality of life questionnaire. Clinical and Translational Allergy, 2025; 15(1): e70038.
ZUBERBIER T, et al. The challenges of chronic urticaria part 1: Epidemiology, immunopathogenesis,
comorbidities, quality of life, and management. World Allergy Organization Journal, 2021; 14(5): 100533.